Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 2Glioma 2Triple Negative Breast Neoplasms 1Recurrence 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Glioblastoma 1Endometrial Neoplasms 1Endometrial Cancer Recurrent 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Temozolomide 3Panobinostat 2Cyclophosphamide 2Bevacizumab 2ribociclib 1marizomib 1dipinacoline glutamate 1cemiplimab 1Topotecan 1TIC10 compound 1Re-Irradiation 1Radiotherapy 1Radiation 1Maintenance 1Irinotecan 1Imiquimod 1Granulocyte-Macrophage Colony-Stimulating Factor 1Erlotinib Hydrochloride 1Drug Tolerance 1Doxorubicin 1Diphtheria-Tetanus Vaccine 1Congresses as Topic 1Cilengitide 1Cetuximab 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Diffuse Intrinsic Pontine Glioma × TIC10 compound × Clear all
NCT03416530 2025-02-14

ONC201 in Pediatric H3 K27M Gliomas

Jazz Pharmaceuticals

Phase 1 Terminated
134 enrolled 1 FDA
CNS

Diffuse Intrinsic Pontine Glioma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡